155 related articles for article (PubMed ID: 3924553)
1. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure].
Heuer LJ; Kaufmann HH
Dtsch Z Verdau Stoffwechselkr; 1985; 45(2):52-8. PubMed ID: 3924553
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
Domke A; Willms B
Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
[TBL] [Abstract][Full Text] [Related]
3. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
4. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
6. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Scheen AJ
Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
[TBL] [Abstract][Full Text] [Related]
8. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
9. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy.
Aubell R; Boehme K; Berchtold P
Arzneimittelforschung; 1983; 33(9):1314-8. PubMed ID: 6357206
[TBL] [Abstract][Full Text] [Related]
10. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
11. Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats.
Yamashita K; Sugawara S; Sakairi I
Horm Metab Res; 1984 Apr; 16(4):179-82. PubMed ID: 6373545
[TBL] [Abstract][Full Text] [Related]
12. Modification in sucrose tolerance test with acarbose, guargum and their combination in patients with non-insulin dependent diabetes.
Shah PK; Lakhotia M; Purohit A; Jain SK; Gupta SK; Bhandari P
J Assoc Physicians India; 1993 Nov; 41(11):703-5. PubMed ID: 8005921
[TBL] [Abstract][Full Text] [Related]
13. [Insulin, glibenclamide plus acarbose in diabetes mellitus?].
Hauner H
Dtsch Med Wochenschr; 1995 Nov; 120(46):1605. PubMed ID: 7588044
[No Abstract] [Full Text] [Related]
14. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
[TBL] [Abstract][Full Text] [Related]
15. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
16. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
Hermanns N; Burkert A; Haak T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
[TBL] [Abstract][Full Text] [Related]
17. Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
Abbink EJ; Pickkers P; van Rosendaal AJ; Lutterman JA; Tack CJ; Russel FG; Smits P
Clin Sci (Lond); 2002 Mar; 102(3):307-14. PubMed ID: 11869171
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
19. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics.
Gerard J; Lefebvre PJ; Luyckx AS
Eur J Clin Pharmacol; 1984; 27(2):233-6. PubMed ID: 6437842
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
Leonhardt W; Hanefeld M; Fischer S; Schulze J
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():45-9. PubMed ID: 8001628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
